Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Hernexeos (zongertinib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Boehringer Ingelheim, Sino Biopharm

Drug class:

HER2 inhibitor

Related drugs:

‹

timigutuzumab (0)

TrastuRel (trastuzumab biosimilar) (0)

Undisclosed HER2Bi-armed ATC (0)

trastuzumab biosimilar (0)

trastuzumab (407)

lapatinib (107)

neratinib (102)

trastuzumab-pkrb (24)

margetuximab-cmkb (18)

zenocutuzumab-zbco (16)

trastuzumab-dttb (11)

zanidatamab-hrii (11)

trastuzumab-strf (9)

trastuzumab-anns (9)

trastuzumab-dkst (9)

trastuzumab-qyyp (9)

pertuzumab/trastuzumab/hyaluronidase-zzxf (3)

trastuzumab/hyaluronidase-oysk (2)

JBJ-08–178–01 (2)

Hercease (trastuzumab biosimilar) (1)

HERtiCAD (trastuzumab biosimilar) (1)

Hervelous (trastuzumab biosimilar) (1)

EG12014 (trastuzumab biosimilar) (1)

sevabertinib (1)

TX05 (trastuzumab biosimilar) (1)

ALT02 (trastuzumab biosimilar) (0)

trastuzumab biosimilar (AP062) (0)

DA 3111 (trastuzumab biosimilar) (0)

HER-2/neu peptide vaccine (0)

HER2 t-haNK (0)

Hervycta (trastuzumab biosimilar) (0)

JNJ-26483327 (0)

diznalimgene lisbac (0)

MVA-BN-HER2 (0)

NeuCeptin (trastuzumab biosimilar) (0)

nelipepimut-S (0)

lapuleucel-T (0)

pertuzumab-dpzb (0)

ertumaxomab (0)

trastuzumab biosimilar (SIBP-01) (0)

trastuzumab biosimilar (0)

timigutuzumab (0)

TrastuRel (trastuzumab biosimilar) (0)

Undisclosed HER2Bi-armed ATC (0)

trastuzumab biosimilar (0)

›

HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	zongertinib Sensitive: C2 – Inclusion Criteria zongertinib Sensitive : C2	zongertinib Sensitive: C2 – Inclusion Criteria zongertinib Sensitive : C2
HER-2 overexpression	Solid Tumor	HER-2 overexpression	Solid Tumor	zongertinib Sensitive: C2 – Inclusion Criteria zongertinib Sensitive : C2	zongertinib Sensitive: C2 – Inclusion Criteria zongertinib Sensitive : C2
HER-2 mutation	Solid Tumor	HER-2 mutation	Solid Tumor	zongertinib Sensitive: C2 – Inclusion Criteria zongertinib Sensitive : C2	zongertinib Sensitive: C2 – Inclusion Criteria zongertinib Sensitive : C2
HER-2 amplification	Solid Tumor	HER-2 amplification	Solid Tumor	zongertinib Sensitive: C2 – Inclusion Criteria zongertinib Sensitive : C2	zongertinib Sensitive: C2 – Inclusion Criteria zongertinib Sensitive : C2
HER-2 positive	Cholangiocarcinoma	HER-2 positive	Cholangiocarcinoma	zongertinib Sensitive: C3 – Early Trials zongertinib Sensitive : C3	zongertinib Sensitive: C3 – Early Trials zongertinib Sensitive : C3
HER-2 positive	Esophageal Cancer	HER-2 positive	Esophageal Cancer	zongertinib Sensitive: C3 – Early Trials zongertinib Sensitive : C3	zongertinib Sensitive: C3 – Early Trials zongertinib Sensitive : C3
HER-2 rearrangement	Solid Tumor	HER-2 rearrangement	Solid Tumor	zongertinib Sensitive: C3 – Early Trials zongertinib Sensitive : C3	zongertinib Sensitive: C3 – Early Trials zongertinib Sensitive : C3
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	zongertinib Sensitive: C3 – Early Trials zongertinib Sensitive : C3	zongertinib Sensitive: C3 – Early Trials zongertinib Sensitive : C3
HER-2 mutation	Esophageal Cancer	HER-2 mutation	Esophageal Cancer	zongertinib Sensitive: C4 – Case Studies zongertinib Sensitive : C4	zongertinib Sensitive: C4 – Case Studies zongertinib Sensitive : C4
HER-2 mutation	Cholangiocarcinoma	HER-2 mutation	Cholangiocarcinoma	zongertinib Sensitive: C4 – Case Studies zongertinib Sensitive : C4	zongertinib Sensitive: C4 – Case Studies zongertinib Sensitive : C4